Engineered Solid Lipid Nanoparticles and Nanostructured Lipid Carriers As New Generations of Blood-Brain Barrier Transmitters Publisher Pubmed



Amiri M^{1, 2} ; Jafari S^{1, 2} ; Kurd M³ ; Mohamadpour H⁴ ; Khayati M⁴ ; Ghobadinezhad F^{2, 5} ; Tavallaei O^{1, 2} ; Derakhshankhah H^{1, 2} ; Sadegh Malvajerd S^{2, 6} ; Izadi Z^{1, 2} Show Affiliations
Source: ACS Chemical Neuroscience Published:2021

Abstract

The blood-brain barrier (BBB) is considered as the most challenging barrier in brain drug delivery. Indeed, there is a definite link between the BBB integrity defects and central nervous systems (CNS) disorders, such as neurodegenerative diseases and brain cancers, increasing concerns in the contemporary era because of the inability of most therapeutic approaches. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) have already been identified as having several advantages in facilitating the transportation of hydrophilic and hydrophobic agents across the BBB. This review first explains BBB functions and its challenges in brain drug delivery, followed by a brief description of nanoparticle-based drug delivery for brain diseases. A detailed presentation of recent progressions in optimizing SLNs and NLCs for controlled release drug delivery, gene therapy, targeted drug delivery, and diagnosis of neurodegenerative diseases and brain cancers is approached. Finally, the problems, challenges, and future perspectives in optimizing these carriers for potential clinical application were described briefly. ©